High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study
Objective: Assess the percentages of advanced Parkinson’s disease (APD) patients treated with levodopa-carbidopa intestinal gel (LCIG) as a monotherapy or with add-on PD medications and…Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay
Objective: To apply an ultrasonication-based misfolded protein amplification to the evaluation of α-synuclein aggregates in CSF, and to investigate their clinical significances in Parkinson’s disease…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.
Objective: To evaluate the efficacy of the 5-Hydroxytryptophan (5-HTP) on levodopa-induced motor complications in patients with Parkinson's disease (PD). Background: Several studies have indicated that…Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study
Objective: To objectively evaluate the real-world impact of carbidopa/levodopa enteral suspension (CLES) on motor symptoms in patients with advanced Parkinson’s disease (PD) in USA. Background:…The French NS-PARK/FCRIN network: a 5-year balance sheet
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity. Background: The French Clinical Research Infrastructure network FCRIN is…Does Gait in Real Life differ between People with Parkinson’s Disease and Healthy Controls?
Objective: We investigated whether: 1) gait in daily life differs in people with Parkinson’s disease (PD) compared to healthy controls (HC), and 2) the length…Assessment of Neuropsychological Outcomes Using a New Multiple Source, Constant- Current Rechargeable Deep Brain Stimulation System for the Treatment of Parkinson’s Disease – INTREPID Study
Objective: To evaluate neuropsychological outcomes in subjects participating in the INTREPID randomized controlled trial (RCT). Background: Neuropsychological evaluation in the context of Deep Brain Stimulation…
- « Previous Page
- 1
- …
- 211
- 212
- 213
- 214
- 215
- …
- 217
- Next Page »